Advances in intravesical drug delivery systems to treat bladder cancer

Int J Pharm. 2017 Oct 30;532(1):105-117. doi: 10.1016/j.ijpharm.2017.08.120. Epub 2017 Sep 1.

Abstract

Chemotherapeutic agents administered intravesically to treat bladder cancer have limited efficacy due to periodic dilution and wash-out during urine formation and elimination. This review describes the pathophysiology, prevalence and staging of bladder cancer, and discusses several formulation strategies used to improve drug residence within the bladder. These include the use of amphiphilic copolymers, mucoadhesive formulations, hydrogels, floating systems, and liposomes. Various in vitro and in vivo models recently employed for intravesical drug delivery studies are discussed. Some of the challenges that have prevented the clinical use of some promising formulations are identified.

Keywords: Bladder cancer; Floating; In situ gelling systems; Intravesical drug delivery; Mucoadhesive; Particulate delivery systems.

Publication types

  • Review

MeSH terms

  • Administration, Intravesical
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Drug Delivery Systems*
  • Humans
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / metabolism
  • Urinary Bladder Neoplasms / pathology

Substances

  • Antineoplastic Agents